



An open-label dosing study to evaluate the safety and effects of a dietary plant derived polysaccharide supplement on the N-glycosylation status of serum glycoproteins in healthy subjects

Azita Alavi, Owen Fraser, Edward Tarelli, Martin J Bland, John S Axford

► To cite this version:

Azita Alavi, Owen Fraser, Edward Tarelli, Martin J Bland, John S Axford. An open-label dosing study to evaluate the safety and effects of a dietary plant derived polysaccharide supplement on the N-glycosylation status of serum glycoproteins in healthy subjects. *European Journal of Clinical Nutrition*, 2011, 10.1038/ejcn.2010.263 . hal-00608019

HAL Id: hal-00608019

<https://hal.science/hal-00608019>

Submitted on 12 Jul 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

An open-label dosing study to evaluate the safety and effects of a dietary plant derived polysaccharide supplement on the *N*-glycosylation status of serum glycoproteins in healthy subjects

Azita Alavi ¹, Owen Fraser ¹, Edward Tarelli², Martin Bland³ and John Axford¹

¹The Sir Joseph Hotung Centre for Musculoskeletal Disorders, Division of Cellular and Molecular Medicine, St George's University of London, London, UK. ² The Biomix Centre, Division of Bi- Medical Sciences, St George's University of London, London, UK. ³ Department of Health Sciences, University of York, York, UK.

Correspondence:

Azita Alavi , The Sir Joseph Hotung Centre for Musculoskeletal Disorders, Division of Cellular and Molecular Medicine, St George's University of London, London SW17 0RE, UK

E-mail: aalavi@sgul.ac.uk, Tel: +44 (0)208 2666802 / (0)208 7253693, Fax: +44 (0) 208 2666814

Running Title:

Dietary plant derived polysaccharide supplement and serum protein *N*-glycosylation changes

Funding:

AA and OF were supported by grant No: RKC0021 from the Research & Development Division of Mannatech, Incorporated, Texas, USA.

Abstract

Background: The functional role of dietary carbohydrates in nutrition is one of the most complex and at times controversial areas in nutritional science. *In-vitro and in-vivo* studies suggest that certain dietary saccharide biopolymers can have bifidogenic and or immunomodulatory effects, and that some could represent preferential substrates or precursors that can impact cellular glycosylation.

Objective: Examine the impact of oral ingestion of a standardized dietary plant derived polydisperse polysaccharide supplement (AA) on the *N*-glycosylation status of serum glycoproteins in a cohort of healthy individuals.

Design: An open label study was used. The study was in two phases; pilot study (n=6 individuals) to assess safety and dose, and a larger study (n=12) to evaluate specific glycosylation changes. Serum *N*-glycosylation profiles, using mass spectrometry, were monitored at weekly intervals, for seven weeks, to evaluate baseline levels and normal fluctuations. The individuals were then monitored for a further seven weeks, during which time increasing doses of AA were ingested (1.3-5.2 g/day).

Results: No adverse events were encountered. AA supplementation resulted in distinct changes in the relative intensities of seven biantennary *N*-glycans ($p < 0.001$), and a significant overall shift towards increased sialylation. Regression analysis revealed a dose dependent decrease in mono- and di-galactosylated structures (coefficient -0.130 decrease/week: $p = 0.02$ and -0.690 : $p = 0.005$), and a concomitant increase in disialylated glycans ($\times 1.083$: $p < 0.05$).

Conclusions: Supplementation with the dietary plant derived polysaccharides in AA resulted in significant changes in serum protein *N*-glycosylation in healthy individuals. How this occurs and whether it has biological significance remains to be evaluated.

Keywords: Dietary plant polysaccharides; Serum glycosylation; *N*-glycans; Dietary fiber; Glycomodifications; Sialylation.

Introduction

Fuelled by the current interest in the link between diet and health (Ma et al. 2008, Estruch et al. 2009, Lomax and Calder 2009, Schiffrin et al. 2009) there is now a surge of research by various groups into the biological activities and potential beneficial effects of dietary saccharide biopolymers (Courtois 2009, Rideout et al. 2008, Graff et al. 2009, Schepetkin and Quinn 2006, Cumashi et al. 2007, Vos et al. 2007, Bruzzese et al. 2009, Chan et al. 2009, Jacobs et al. 2009, Weickert and Pfeiffer 2008, Liu et al. 2009). These biopolymers represent a broad range of structurally diverse (Schepetkin and Quinn 2006), non- or low-digestible, dietary soluble fibers that have been derived from different species of flora including higher plants, fungi, lichens and algae, and have been demonstrated (*in-vitro* or *in-vivo*) to affect beneficially one or more target cellular or body functions (Graff et al. 2009, Ma et al. 2008, Bruzzese et al. 2009, Chan et al. 2009, Lomax and Calder 2009, van den Heuvel et al. 2009, Courtois 2009, Hua et al. 2007, Ho et al. 2007, Kim and Joo 2008, Cumashi et al. 2007, Vos et al. 2007).

The physiological effects attributed to these “functional” polysaccharides can be divided into six main categories: 1) beneficial effects on colonic microflora (Jacobs et al. 2009) and gastrointestinal physiology; i.e. acting as a prebiotic (Lomax and Calder 2009, de Vrese and Schrezenmeir 2008, Macfarlane et al. 2008); 2) immunomodulatory effects (Leung et al. 2006, Graff et al. 2009, Bruzzese et al. 2009, Benyacoub et al. 2008, Kim and Joo 2008, Vos et al. 2007, Cumashi et al. 2007, Schepetkin and Quinn 2006, Mizuno et al. 2009, Hua et al. 2007, Burrows et al. 2009); 3) anti-angiogenetic (Cumashi et al. 2007) and anti-tumour effects (Chan et al. 2009, Liu et al. 2009); 4) altered lipid metabolism (Chen and Huang 2009, Rideout et al. 2008); 5) improved bioavailability of essential minerals (van den Heuvel et al. 2009, Bo et al.

2006); and 6) other beneficial health effects such as enhanced production of growth factors involved in re-epithelization and wound healing (Jettanacheawchankit et al. 2009).

In this respect, many of the dietary saccharide polymers studied (isolated from >35 species) (Schepetkin and Quinn 2006), exhibiting multifunctional physicochemical and physiological characteristics, are now being redefined as secondary metabolites (Courtois 2009, Macfarlane et al. 2008, Vos et al. 2007, Weickert and Pfeiffer 2008), and or biological response modifiers (BRMs) (Leung et al. 2006).

These BRM polysaccharides (Table 1) have diverse structural complexity, and belong to a wide range of low or high MW, soluble or insoluble, acidic or neutral, homo- or hetero-polymers, which may or may not undergo varying degrees of degradation in the digestive tract either by bacterial enzymes or by specific conditions associated with the digestive process (Courtois 2009, Arasaradnam et al. 2009, van den Broek et al. 2008, Sinnott et al. 2007, Jacobs et al. 2009, Macfarlane et al. 2008, Schiffrin et al. 2009). Recent evidence suggests that the potential for these polysaccharides to undergo some degree of degradation is highly dependent on the metabolic potential encoded by the combined genomes of the gut microbiota (Tuohy et al. 2009, Arasaradnam et al. 2009).

Current studies into the link between the bioconversion of these dietary polysaccharides, their bioavailability and their downstream effects on the host metabolism and physiology are utilizing metabolomics and metagenomics approaches (Jacobs et al. 2009). These and other innovative approaches in the field of colonic fermentation (Arasaradnam et al. 2009, Chassard et al. 2007) are providing novel insights into gut microbial-human mutualism (Possemiers et al. 2009), its

impact on regulating human health and disease, and the importance of dietary modulation (Schiffrin et al. 2009, Leung et al. 2006, Lomax and Calder 2009, Bruzzese et al. 2009, Macfarlane et al. 2008, Tuohy et al. 2009, Liu et al. 2009).

Although many of the physiological traits attributed to dietary polysaccharides may be secondary, i.e. related to their effects on the gut microflora and its biochemical activities (Schiffrin et al. 2009), evidence from various pharmacodynamic and pharmacokinetic studies also indicate microflora-independent immunomodulatory effects (Schepetkin and Quinn 2006, Ho et al. 2007, Hua et al. 2007).

This “direct” immunomodulatory effect is instigated by the binding of certain BRM polysaccharides (e.g. β -glucans) (Dalmo and Bogwald 2008) to specific receptors on immune cells in the gut associated lymphoid tissues, and results in the intracellular activation of signal transducers and transcription factors that are associated with various effector functions of the immune response (Graff et al. 2009, Schepetkin and Quinn 2006, Vos et al. 2007, Paur et al. 2008, Mizuno et al. 2009, Hua et al. 2007, Vetvicka et al. 1996, Ho et al. 2007, Burrows et al. 2009).

Although the potential mechanisms of the interaction and the subsequent signal transduction pathways are not fully understood, the evidence supports the direct binding of BRM polysaccharides (or their fragments) to pattern recognition receptors (PRRs). These receptors are key players in the immune response (receptors for recognition of microbial polysaccharides) and include toll like receptors (Leung et al. 2006, Graff et al. 2009, Hua et al. 2007, Dalmo and Bogwald 2008), non-Toll PRRs (e.g. β -glucan receptor or dectin-1), complement receptor CR3, and certain transmembrane lectins (Gunning et al. 2009, Vetvicka et al. 1996, Vos et al. 2007). Recognition via these PRRs can result in intracellular signaling cascades e.g. activation of

protein kinases or NF- κ B. This can in turn result in subsequent activation or inactivation of a wide spectrum of target genes involved in the regulation of a variety of cellular responses, such as expression of various cell surface receptors (Kim and Joo 2008) and cytokine production (Jettanacheawchankit et al. 2009, Paur et al. 2008, Leung et al. 2006, Schepetkin and Quinn 2006, Cumashi et al. 2007, Dalmo and Bogwald 2008).

One of the primary immunomodulatory effects of BRM polysaccharides is to promote or alter various leukocyte activities, in particular those of macrophages (Schepetkin and Quinn 2006, Leung et al. 2006) and immune-regulatory $\gamma\delta$ T cells (a subpopulation of intraepithelial lymphocytes in the gastrointestinal tract) (Graff et al. 2009), via changes in cytokine expression (Yoshino et al. 2000, Hua et al. 2007, Benyacoub et al. 2008, Kim and Joo 2008, Schiffrin et al. 2009, Burrows et al. 2009). This in turn can impact both the innate and adaptive arms of the immune response and thus result in activation or dampening of these responses (Mizuno et al. 2009, Ho et al. 2007, Schepetkin and Quinn 2006, Cumashi et al. 2007, Vos et al. 2007, Graff et al. 2009).

Dietary polysaccharide induced immunomodulatory activities of note include: increased macrophage cytotoxic and phagocytic activities, altered pro- and anti-inflammatory (Kim and Joo 2008, Benyacoub et al. 2008, Leung et al. 2006, Ho et al. 2007, Schepetkin and Quinn 2006, Mizuno et al. 2009, Schiffrin et al. 2009) and Th1-Th2 balance (Yoshino et al. 2000, Vos et al. 2007, Burrows et al. 2009), as well as altered expression of certain adhesion molecules (Graff et al. 2009, Ho et al. 2007, Schepetkin and Quinn 2006, Yoshino et al. 2000, Cumashi et al. 2007). All of which supports the notion that certain dietary plant polysaccharides may have significant immunomodulatory potential (Benyacoub et al. 2008, Trinchero et al. 2009, Schepetkin and Quinn 2006, Cumashi et al. 2007, Ho et al. 2007, Tuohy et al. 2009, Burrows et al. 2009).

In view of this and given the important link between changes in the immune response and the glycosylation of various effector glycoproteins (Alavi and Axford 2008), the aim of this study was to examine the possible affects, if any, that oral administration of dietary plant polysaccharides may have on the glycosylation status of serum glycoproteins in a cohort of healthy subjects. We chose a commercial, mixed saccharide dietary supplement (AA), the constituents of which have previously been shown to exhibit prebiotic (Sinnott et al. 2007) as well as possible immunomodulatory activities (Lefkowitz et al. 2000, Koetzner et al. 2009), and for the purposes of this study have no known reported toxicity or negative side effects associated with their use in human subjects (Stancil and Hicks 2009).

Using AA we carried out an open-label dosing study to first evaluate safety of increased doses, and second to monitor the affect on the N-glycosylation status of serum glycoproteins in healthy subjects.

Materials and methods

Study Cohort

Healthy volunteers were recruited from the staff at St George's University of London. The study design was approved by the Ethics Committee and volunteers gave written informed consent.

Supplement

The supplement was Advanced Ambrotose™ (AA) powder (provided by Mannatech, Incorporated, USA). AA is a plant derived dietary supplement that contains a standardized mixture of partially purified polydisperse saccharide biopolymers: aloe vera gel powder (containing glucomannan based polysaccharides), arabinogalactan (high-M.wt soluble arabinose and galactose containing dietary fiber), gum ghatti and gum tragacanth (mainly soluble mixture of complex galactose polymers; with other saccharide constituents including arabinose, rhamnose, fucose, glucose, mannose, xylose, and uronic acids), glucosamine (plant derived supplemental glucosamine HCl), *Undaria pinnatifida* fucoidans (sulfated fucose polymer that contains other monosaccharides, galactose and mannose, derived from edible brown seaweed), and rice starch.

Study Design

An open-label dosing study was set up. The study was carried out in two phases.

Phase 1: Pilot study to establish safety and dose necessary to impact serum N-glycosylation profiles. 6 individuals (age range 28-55; 3 females), ingested increasing doses of AA supplement (increased by 1.3g/week) for seven weeks; starting with 1.3g/day for week 1, and reaching

9.1g/day at week 7). From week 7 to week 11, the group was divided into two arms; three stopped their supplement whilst the other three volunteers continued with supplementation at increasing doses (reaching 14.3g/day by week 11).

Phase 2: A larger study to evaluate glycosylation changes pre- and during-supplementation. 12 volunteers (age range 22-40; 6 females), were followed for 16 weeks. The first 7 weeks, designated as the pre-supplementation period (week -7 to 0), was to establish baseline serum N-glycosylation patterns and normal fluctuations. Following this period, the individuals ingested increasing doses of AA supplement (week 1-4 at 1.3g/day; week 5-6 at 2.6 g/day and week 7-8 at 5.2g/day). This was followed by a final week with no supplement intake (week 9).

Sample collection

Serum was extracted from blood samples and stored at -40°C. Samples were tested in a blind fashion. The codes were not revealed until the study was completed.

Glycosylation Analysis

Serum (40µl) glycoproteins were deglycosylated using a Peptide N-Glycosidase-F (New England BioLabs Inc, UK) according to the manufacturer's instructions. Released N-glycans were isolated by C18 (Supelco, UK), and graphitized carbon columns, freeze-dried, reconstituted in 100µL deionised water, ready for Glycan profiling by Matrix assisted laser desorption ionisation time-of-flight mass spectrometry (MS; Kratos Analytical, Ltd, UK), set in positive linear mode and calibrated with a dextran ladder. Dihydroxy-benzoic acid was used as the matrix.

Statistical analysis

Where necessary the data were log transformed. To allow for time trends analysis of covariance with time as a continuous predictor and subject as a categorical factor was used. For each glycan structure, two regression models were fitted. The first ignored AA and fitted a straight line relationship with time. The second allowed for different regression lines in the pre-supplement and supplement periods. These two models were compared using an F test. The difference between the sums of squares was calculated. The ratio of this to the residual mean square for the larger, two period model = F ratio; used to test effect of AA.

Correction for multiple comparisons: The Bonferroni method was applied and significance was set at $p \leq 0.006$.

Dose-Effect: Only the data following the start of AA were used to analyse regression of each glycan on dose and subject as a categorical factor. Time was included as a second covariate (to allow for possible time trends); such that if there was a significant dose trend even after adjustment for time, the effect of dose was fairly secure.

Results

Safety and compliance

Phase 1: All 6 subjects completed the trial. AA was well tolerated even at high doses, with no adverse reactions.

Phase 2: All six male and five female volunteers completed the trial. However, due to palatability issues at high doses, 4/5 female volunteers stopped supplementation earlier than planned; two at week 6 and two at week 7. One female volunteer withdrew at week 1 (due to palatability issues), and had data for pre-AA phase only, and was therefore omitted from the analysis.

Serum N-glycan analysis

Serum N-glycan profiles for each individual at weekly intervals were examined. Eight main biantennary serum glycoprotein derived N-glycan structures corresponding to different m/z values were identified (Figure 1). Peak intensities were analyzed.

Phase 1: analysis of the data from the pilot study demonstrated changes in the serum N-glycan profile in response to increasing doses of AA supplementation. Example of the observed changes for each of the 6 volunteers, at four time points, for four of the glycans, G0, G1, G1F and A2, are shown (Figure 2). The time points chosen were time =0 (representing baseline values), time = 1 (demonstrating that changes in serum protein glycosylation were evident within 1 week of supplementation at 1.3g/ day;), time = 7 (9.1g/day; time point at which the group were subdivided into 2 arms; 3 individuals continued with their oral supplementation at increasing doses, whilst the remaining 3 discontinued their supplementation), and time = 11 (the end of the

study demonstrating possible differences between the serum glycosylation profile of the individuals who continued compared with those that discontinued with their AA supplementation).

Week 0-7: All apart from the monosialylated A1 glycans (not shown), showed some degree of change in response to AA supplementation.

Week 7-11: Comparisons of the glycan profiles in the 3 individuals that discontinued with those that continued AA supplementation showed differences. These differences were confined mainly to the neutral glycans (G0F, G1, G1F, G2 and G2F) and were particularly noticeable for G1F where the levels reverted (increased) towards baseline (week=0) when AA was discontinued (Figure 2).

Phase 2: The seven week pre-supplementation monitoring of serum protein glycan profiles allowed us to evaluate and monitor normal glycosylation fluctuations and to establish statistically meaningful baseline levels. Comparison of the glycan profiles during the supplementation period with the time trends observed during the pre-supplementation period detected distinct changes in the relative intensities of 7/8 glycans studied. These changes were particularly striking within the first 1-2 weeks of supplementation (Figure 3). G0 was the exception; showing major fluctuations in the pre- as well as supplementation period.

Analysis of covariance utilizing the two regression model, was used to assess the strength of evidence that serum glycosylation changes followed AA supplementation. A graphical example of the model as applied to the analysis of the data for G2 glycans is given (Figure 4). Using this analysis, AA supplementation was found to result in significant changes in the levels of all the

serum protein derived N-linked glycans (G0F, G1, G1F, G2, G2F, A1 and A2; $p < 0.001$) except G0 ($p = 0.2$).

Dose effect

Regression analysis (with time as a second covariate) following the start of AA was used to assess the strength of evidence that change did occur following supplementation with AA and to examine the effect of dose. The results (Table 2) show dose effects for G1 and G2; the levels of which decreased significantly with increasing AA dose (coefficient factor by which mean glycan levels are multiplied /week = -0.130 and -0.690 ; $p = 0.02$ and 0.005 respectively), and for A2; the levels of which increased significantly with increasing AA dose (Coefficient factor = 1.083 ; $p = 0.005$).

Discussion

Our study reports novel findings showing that the ingestion of a standardized mixture of plant derived polysaccharides can induce significant changes in the *N*-glycosylation status of serum glycoproteins in normal healthy individuals. AA supplementation caused an overall, dose dependent, shift towards increased sialylation; resulting in significantly lower levels of neutral glycans (G1 and G2: -0.130 and -0.690 per week: respectively), and increased levels of fully processed, sialylated, glycans (A2: by a factor of 1.083 per week).

Given that glycosylation is a key post-translational modification that can significantly affect the overall biophysical and biochemical functions of proteins (Alavi and Axford 2008, Biol-N'garagba and Louisot 2003), the observed shift in the *N*-glycosylation status of serum glycoproteins in response to AA supplementation may be significant and could reflect changes in one or more physiological parameters.

Interpretation of the biological significance of the observed shift towards more sialylated serum glycoproteins is complex (Alavi and Axford 2008) and requires further more detailed structure-function examination of given serum glycoproteins (e.g., IgG). However, what is known is that increased levels of sialic acid can affect absorption, serum half-life, and clearance from the serum, as well as the physical, chemical and immunogenic properties of various key serum glycoproteins (Alavi and Axford 2008, Bork et al. 2009, Schauer 2009).

Indeed, sialylation changes can play a key role in many aspects of the immune response, in particular in relation to the regulation of inflammatory processes, as in the case of IgG, where sialylation has been shown to act as “switch”. The presence of sialylation is associated with the steady state, normal, anti-inflammatory function of IgG, whilst its absence is associated with the pro-inflammatory effector function (Alavi and Axford 2008, Anthony et al. 2008).

However, with this in mind, it is important to note that the elucidation of a specific physiological role for a given glycan modification, such as sialylation, poses formidable challenge. The presence or absence of a particular sugar residue, at a particular glycosylation site on a given protein, may have different roles in different biological settings. In the case of sialic acid, this is further complicated by the fact that sialylation is linkage-specific, and that the presence of the different forms of sialic acid may give rise to very different biological scenarios (Alavi and Axford 2008, Schauer 2009). Further research is therefore needed to more clearly elucidate specific effects and their consequent biological significance.

Although the question of whether these serum glycosylation changes are directly linked to the constituents of AA per se, or the affect of these on gut microflora (Sinnott et al. 2007) requires further investigation, the novel finding that small amounts of a polydisperse mixture of dietary polysaccharides can alter the glycosylation of serum proteins is unexpected and intriguing. This is especially true as it provides a potential mechanism through which dietary polysaccharides may alter the effector functions of circulating molecules. This notion is particularly relevant when one considers the fact that, time and again, cross-sectional (Bo et al. 2006) and longitudinal (Estruch et al. 2009) studies indicate an association between dietary fiber intake and levels of inflammatory serum markers (e.g. an inverse correlation with IL-6 and TNF- α receptor-2) (Ma et al. 2008). Continued efficacy studies employing randomized placebo-controlled trials examining AA and its specific components are warranted to evaluate possible effect(s).

In conclusion, we have demonstrated that supplementation with dietary plant polysaccharides in AA can result in significant serum protein glycomodifications in normal healthy individuals.

These findings are interesting and merit further research, where it is hoped that an integrative approach using glycomics together with other -omics such as metabolomics and metagenomics; focusing on the gut associated microbe-host mutualism and its impact on physiology, can help unravel the exogenous and endogenous effects of dietary components and hence generate novel hypotheses for innovative dietary interventions that may impact health.

Abbreviations

AA: Advanced AmbrotoseTM powder; A1: Monosialylated; A2: Disialylated; BRM: Biological response modifiers; CR3: Complement receptor type 3; $\gamma\delta$ T: Gamma delta T cells; G0: Agalactosylated; G1: Monogalactosylated; G2: Digalactosylated; IL-: Interleukin; MS: Matrix assisted laser desorption ionisation time-of-flight mass spectrometry; MW: Molecular weights; NF- κ B: Nuclear transcription factor kappa B; NK: Natural killer cells; PRRs: Pattern recognition receptors; Th1/Th2: Helper T cells; TLRs: Toll like receptors; TNF: Tumour necrosis factor.

Conflict of interest

AA and OF were in receipt of research grants from the R&D Division of Mannatech, Incorporated.

JA was, from 2002-2007, an independent board director, shareholder and consultant for Mannatech, Incorporated.

Mannatech, Incorporated had no role in the conception or design of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or the decision to publish.

Contributions:

AA, JA and ET conceived and designed the study. AA carried out the study and performed the analysis and interpretation of the data, as well as coordinated and drafted the manuscript. OF and ET carried out the MS analysis. MB performed the statistical analysis. All authors have read and approved the final paper.

References

- Alavi, A. & J. S. Axford (2008) Sweet and sour: the impact of sugars on disease. *Rheumatology (Oxford)*, 47, 760-70.
- Anthony, R. M., F. Nimmerjahn, D. J. Ashline, V. N. Reinhold, J. C. Paulson & J. V. Ravetch (2008) Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. *Science*, 320, 373-6.
- Arasaradnam, R. P., M. W. Pharaoh, G. J. Williams, C. U. Nwokolo, K. D. Bardhan & S. Kumar (2009) Colonic fermentation--more than meets the nose. *Med Hypotheses*, 73, 753-6.
- Benyacoub, J., F. Rochat, K. Y. Saudan, I. Rochat, N. Antille, C. Cherbut, T. von der Weid, E. J. Schiffrin & S. Blum (2008) Feeding a diet containing a fructooligosaccharide mix can enhance Salmonella vaccine efficacy in mice. *J Nutr*, 138, 123-9.
- Biol-N'garagba M, C. & P. Louisot (2003) Regulation of the intestinal glycoprotein glycosylation during postnatal development: role of hormonal and nutritional factors. *Biochimie*, 85, 331-52.
- Bo, S., M. Durazzo, S. Guidi, M. Carello, C. Sacerdote, B. Silli, R. Rosato, M. Cassader, L. Gentile & G. Pagano (2006) Dietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohort. *Am J Clin Nutr*, 84, 1062-9.
- Bork, K., R. Horstkorte & W. Weidemann (2009) Increasing the sialylation of therapeutic glycoproteins: the potential of the sialic acid biosynthetic pathway. *J Pharm Sci*, 98, 3499-508.
- Bruzzese, E., M. Volpicelli, V. Squeglia, D. Bruzzese, F. Salvini, M. Bisceglia, P. Lionetti, M. Cinquetti, G. Iacono, S. Amarri & A. Guarino (2009) A formula containing galacto- and fructo-oligosaccharides prevents intestinal and extra-intestinal infections: an observational study. *Clin Nutr*, 28, 156-61.
- Burrows, M., D. Assundani, E. Celis, F. Tufaro, A. Tanaka & W. G. Bradley (2009) Oral administration of PPC enhances antigen-specific CD8⁺ T cell responses while reducing IgE levels in sensitized mice. *BMC Complement Altern Med*, 9, 49.
- Chan, G. C., W. K. Chan & D. M. Sze (2009) The effects of beta-glucan on human immune and cancer cells. *J Hematol Oncol*, 2, 25.
- Chassard, C., V. Goumy, M. Leclerc, C. Del'homme & A. Bernalier-Donadille (2007) Characterization of the xylan-degrading microbial community from human faeces. *FEMS Microbiol Ecol*, 61, 121-31.
- Chen, J. & X. F. Huang (2009) The effects of diets enriched in beta-glucans on blood lipoprotein concentrations. *J Clin Lipidology*, 3, 154-158.
- Courtois, J. (2009) Oligosaccharides from land plants and algae: production and applications in therapeutics and biotechnology. *Curr Opin Microbiol*, 12, 261-73.
- Cumashi, A., N. A. Ushakova, M. E. Preobrazhenskaya, A. D'Incecco, A. Piccoli, L. Totani, N. Tinari, G. E. Morozevich, A. E. Berman, M. I. Bilan, A. I. Usov, N. E. Ustyuzhanina, A. A. Grachev, C. J. Sanderson, M. Kelly, G. A. Rabinovich, S. Iacobelli & N. E. Nifantiev (2007) A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. *Glycobiology*, 17, 541-52.

- Dalmo, R. A. & J. Bogwald (2008) Beta-glucans as conductors of immune symphonies. *Fish Shellfish Immunol*, 25, 384-96.
- de Vrese, M. & J. Schrezenmeir (2008) Probiotics, prebiotics, and synbiotics. *Adv Biochem Eng Biotechnol*, 111, 1-66.
- Estruch, R., M. A. Martinez-Gonzalez, D. Corella, J. Basora-Gallisa, V. Ruiz-Gutierrez, M. I. Covas, M. Fiol, E. Gomez-Gracia, M. C. Lopez-Sabater, R. Escoda, M. A. Pena, J. Diez-Espino, C. Lahoz, J. Lapetra, G. Saez & E. Ros (2009) Effects of dietary fibre intake on risk factors for cardiovascular disease in subjects at high risk. *J Epidemiol Community Health*, 63, 582-8.
- Graff, J. C., E. M. Kimmel, B. Freedman, I. A. Schepetkin, J. Holderness, M. T. Quinn, M. A. Jutila & J. F. Hedges (2009) Polysaccharides derived from Yamao (*Funtumia elastica*) prime gammadelta T cells in vitro and enhance innate immune responses in vivo. *Int Immunopharmacol*, 9, 1313-22.
- Gunning, A. P., R. J. Bongaerts & V. J. Morris (2009) Recognition of galactan components of pectin by galectin-3. *FASEB J*, 23, 415-24.
- Ho, Y. W., J. S. Yeung, P. K. Chiu, W. M. Tang, Z. B. Lin, R. Y. Man & C. S. Lau (2007) Ganoderma lucidum polysaccharide peptide reduced the production of proinflammatory cytokines in activated rheumatoid synovial fibroblast. *Mol Cell Biochem*, 301, 173-9.
- Hua, K. F., H. Y. Hsu, L. K. Chao, S. T. Chen, W. B. Yang, J. Hsu & C. H. Wong (2007) Ganoderma lucidum polysaccharides enhance CD14 endocytosis of LPS and promote TLR4 signal transduction of cytokine expression. *J Cell Physiol*, 212, 537-50.
- Jacobs, D. M., E. Gaudier, J. van Duynhoven & E. E. Vaughan (2009) Non-digestible food ingredients, colonic microbiota and the impact on gut health and immunity: a role for metabolomics. *Curr Drug Metab*, 10, 41-54.
- Jettanacheawchankit, S., S. Sasithanasate, P. Sangvanich, W. Banlunara & P. Thunyakitpisal (2009) Acemannan stimulates gingival fibroblast proliferation; expressions of keratinocyte growth factor-1, vascular endothelial growth factor, and type I collagen; and wound healing. *J Pharmacol Sci*, 109, 525-31.
- Kim, M. H. & H. G. Joo (2008) Immunostimulatory effects of fucoidan on bone marrow-derived dendritic cells. *Immunol Lett*, 115, 138-43.
- Koetzner, L., G. Grover, J. Boulet & H. I. Jacoby (2009) Plant-Derived Polysaccharide Supplements Inhibit Dextran Sulfate Sodium-Induced Colitis in the Rat. *Dig Dis Sci*.
- Lefkowitz, D. L., R. Stuart, B. T. Gnade, E. Roberts & S. S. Lefkowitz (2000) Effects of a glyconutrient on macrophage functions. *Int J Immunopharmacol*, 22, 299-308.
- Leung, M. Y., C. Liu, J. C. Koon & K. P. Fung (2006) Polysaccharide biological response modifiers. *Immunol Lett*, 105, 101-14.
- Liu, J., L. Gunn, R. Hansen & J. Yan (2009) Yeast-derived beta-glucan in combination with anti-tumor monoclonal antibody therapy in cancer. *Recent Pat Anticancer Drug Discov*, 4, 101-9.
- Lomax, A. R. & P. C. Calder (2009) Prebiotics, immune function, infection and inflammation: a review of the evidence. *Br J Nutr*, 101, 633-58.
- Ma, Y., J. R. Hebert, W. Li, E. R. Bertone-Johnson, B. Olendzki, S. L. Pagoto, L. Tinker, M. C. Rosal, I. S. Ockene, J. K. Ockene, J. A. Griffith & S. Liu (2008) Association between dietary fiber and markers of systemic inflammation in the Women's Health Initiative Observational Study. *Nutrition*, 24, 941-9.

- Macfarlane, G. T., H. Steed & S. Macfarlane (2008) Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics. *J Appl Microbiol*, 104, 305-44.
- Mizuno, M., Y. Nishitani, T. Hashimoto & K. Kanazawa (2009) Different suppressive effects of fucoidan and lentinan on IL-8 mRNA expression in in vitro gut inflammation. *Biosci Biotechnol Biochem*, 73, 2324-5.
- Paur, I., L. M. Austenaa & R. Blomhoff (2008) Extracts of dietary plants are efficient modulators of nuclear factor kappa B. *Food Chem Toxicol*, 46, 1288-97.
- Possemiers, S., C. Grootaert, J. Vermeiren, G. Gross, M. Marzorati, W. Verstraete & T. Van de Wiele (2009) The intestinal environment in health and disease - recent insights on the potential of intestinal bacteria to influence human health. *Curr Pharm Des*, 15, 2051-65.
- Rideout, T. C., S. V. Harding, P. J. Jones & M. Z. Fan (2008) Guar gum and similar soluble fibers in the regulation of cholesterol metabolism: current understandings and future research priorities. *Vasc Health Risk Manag*, 4, 1023-33.
- Schauer, R. (2009) Sialic acids as regulators of molecular and cellular interactions. *Curr Opin Struct Biol*, 19, 507-14.
- Schepetkin, I. A. & M. T. Quinn (2006) Botanical polysaccharides: macrophage immunomodulation and therapeutic potential. *Int Immunopharmacol*, 6, 317-33.
- Schiffirin, E. J., J. E. Morley, A. Donnet-Hughes & Y. Guigoz (2009) The inflammatory status of the elderly: The intestinal contribution. *Mutat Res*.
- Sinnott, R. A., J. Ramberg, J. M. Kirchner, C. Oubre, C. Duncan, S. Boyd & e. al. (2007) Utilization of arabinogalactan, aloe vera gel polysaccharides, and a mixed saccharide dietary supplement by human colonic bacteria in vitro. *Int J Probiotics Prebiotics*, 2, 97-104.
- Stancil, A. N. & L. H. Hicks (2009) Glyconutrients and perception, cognition, and memory. *Percept Mot Skills*, 108, 259-70.
- Trincherro, J., N. M. Ponce, O. L. Cordoba, M. L. Flores, S. Pampuro, C. A. Stortz, H. Salomon & G. Turk (2009) Antiretroviral activity of fucoidans extracted from the brown seaweed *Adenocystis utricularis*. *Phytother Res*, 23, 707-12.
- Tuohy, K. M., C. Gougoulis, Q. Shen, G. Walton, F. Fava & P. Ramnani (2009) Studying the human gut microbiota in the trans-omics era--focus on metagenomics and metabonomics. *Curr Pharm Des*, 15, 1415-27.
- van den Broek, L. A., S. W. Hinz, G. Beldman, J. P. Vincken & A. G. Voragen (2008) Bifidobacterium carbohydrases-their role in breakdown and synthesis of (potential) prebiotics. *Mol Nutr Food Res*, 52, 146-63.
- van den Heuvel, E. G., T. Muijs, F. Brouns & H. F. Hendriks (2009) Short-chain fructo-oligosaccharides improve magnesium absorption in adolescent girls with a low calcium intake. *Nutr Res*, 29, 229-37.
- Vetvicka, V., B. P. Thornton & G. D. Ross (1996) Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. *J Clin Invest*, 98, 50-61.
- Vos, A. P., L. M'Rabet, B. Stahl, G. Boehm & J. Garssen (2007) Immune-modulatory effects and potential working mechanisms of orally applied nondigestible carbohydrates. *Crit Rev Immunol*, 27, 97-140.
- Weickert, M. O. & A. F. Pfeiffer (2008) Metabolic effects of dietary fiber consumption and prevention of diabetes. *J Nutr*, 138, 439-42.

Yoshino, S., T. Tabata, S. Hazama, N. Iizuka, K. Yamamoto, M. Hirayama, A. Tangoku & M. Oka (2000) Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1/Th2 balance in patients with digestive cancers. *Anticancer Res*, 20, 4707-11.

Figure legends

Figure 1:

Schematic diagram of the serum protein derived biantennary N-linked glycan structures that were analyzed by MS. Eight main biantennary serum glycoprotein derived N-glycan structures were identified. These comprised six neutral and two acidic (sialylated) glycans. The glycans are designated as G0, G1 and G2; according to the number of terminal galactose residues, and A1 and or A2; according to the number of terminal sialic acid residues that decorate the core pentasaccharide (GlcNAc2, Man3). Three of the glycans are fucosylated (F); giving rise to G0F, G1F and G2F structures. Monosialylation and monogalactosylation may occur on either the α 1-3 or α 1-6 arm of the biantennary structures.

Figure 2:

Results from the pilot study; examining possible changes in serum protein N-glycosylation in response to different doses of AA. The MS % intensity for G0, G1, G1F and A2, for each of the 6 volunteers, at four time points is shown. Week 0 (baseline), week1 (AA at 1.3g/ day), week 7 (AA at 9.1g/day) and week 11 (n=3 continued to take increasing doses of AA, reaching a final dose of 14.3g/day, represented by the solid line; and n=3 discontinued their AA supplementation, represented by dashed line, respectively).

Figure 3:

Serum protein N-glycan profiles before and after oral AA supplementation. Plots of MS observations for all subjects for whom there were measurements made before and during AA

supplementation, demonstrating the changes in the eight serum protein derived biantennary *N*-glycans in response to oral AA supplementation (zero time is the last pre-AA measurement). The changes were significant (F test for the effect of AA; $p < 0.001$) for all the serum protein *N*-glycans except G0.

Figure 4:

Example of the two regression model used for the analysis of covariance showing the change in serum protein G2 glycan levels following AA supplementation ($p < 0.001$). For each glycan structure two regression models were fitted. The first ignored AA and fitted a straight line (broken blue line) relationship with time. The second allowed for different regression lines in the pre-supplement and supplement phase (solid black lines; coefficient -0.501 and 0.018 respectively). This was achieved by creating two time variables; the first is time up to AA, but is equal to zero afterwards. The second time variable is time after AA but is equal to zero before AA.

Table 1: Examples of dietary polysaccharides that have been studied in relation to their biological activities

| Dietary Polysaccharides | Features / examples | Biological Functions |
|--|--|---|
| Sulphated polysaccharides; glycosaminoglycans | Heparin-like Fucoidans - obtained from edible seaweed. | Potent antioxidant and anticoagulant properties as well as immunopharmacological properties such as anti-inflammatory activity (Cumashi et al. 2007, Kim and Joo 2008, Mizuno et al. 2009). |
| Glucomannan polysaccharides | Acemannan - obtained from <i>Aloe vera</i> . | Potent immunostimulants (Leung et al. 2006) that also exhibit anti tumour and wound healing properties via induction of fibroblast proliferation and increased type I collagen expression (Jettanacheawchankit et al. 2009, Leung et al. 2006). |
| β glucans; Wide spread homo-polysaccharides (D-glucose monomers linked by glycosidic bonds) with different molecular weights (MW) and degree of branching. | They occur most commonly as the cell wall of yeast, certain fungi and mushrooms (e.g. lentinan). | These exhibit marked anti-tumour (Chan et al. 2009, Liu et al. 2009) and immunostimulatory (Mizuno et al. 2009) activity, affecting both the innate as well as the adaptive arm (Th1 and Th2) of the immune response (Dalmo and Bogwald 2008), and may be effective in controlling blood lipids (Chen and Huang 2009). Generally insoluble (1,3/1,6) β glucan, has greater biological activity than the soluble (1,3/1,4) β glucans. |
| Inulin polysaccharides; Fructans | Fructose polymers \pm terminal glucose. Found in many types of plants. Foods naturally high in inulin include garlic, onion and chicory. | These are associated with immunomodulatory anti-inflammatory effects as well as selective mineral absorption. They have also been implicated in controlling blood lipids (Bruzzese et al. 2009, van den Heuvel et al. 2009, Courtois 2009). |
| Arabinogalactan polysaccharides | Consisting of arabinose and galactose. Major constituents of many gums, including gum gutti and gum tragacanth. | A number of these exhibit immunomodulatory effects via induction of both pro- and anti-inflammatory cytokines (Schepetkin and Quinn 2006) and have been shown to exhibit potent complement-fixing activity and beneficial prebiotic properties, particularly in gastrointestinal functional disorders such as Irritable bowel syndrome, by increasing the colonic contents of short-chain fatty acids. Guar gum has also been implicated in improving blood lipids (Rideout et al. 2008). |

Table 2: Effect of increasing dose of AA supplement on serum protein *N*-glycosylation: Regression analysis of the data demonstrates significant dose effects for G1, G2 and A2 serum protein *N*-glycans.


| Glycans | Dose alone | | Dose adjusted for time | |
|------------------------|-------------|---------|------------------------|---------|
| | Coefficient | p value | Coefficient | p value |
| G0[*] | 1.124 | 0.1 | 0.993 | 0.09 |
| G0F[*] | 0.996 | 0.9 | 1.020 | 0.6 |
| G1[†] | −0.133 | 0.001 | −0.1305 | 0.02 |
| G1F[*] | 0.962 | 0.3 | 1.016 | 0.7 |
| G2[†] | −0.976 | <0.001 | −0.690 | 0.005 |
| G2F[†] | −0.226 | 0.001 | −0.170 | 0.2 |
| A1[†] | 0.532 | 0.007 | 0.669 | 0.1 |
| A2[*] | 1.082 | 0.002 | 1.083 | 0.005 |

For the purposes of statistical analysis, log transformation was applied to those glycans that exhibited a skewed distribution (more variable at high levels than at low levels).

[†] *Analysed on natural scale; coefficient = increase in mean sugar per week.*

^{*} *Analysed on logarithmic scale; coefficient = factor by which mean sugar is multiplied per week.*

Figure 1



- Key:
- N-acetylglucosamine (GlcNAc)
 - Mannose (Man)
 - Galactose (Gal)
 - ▼ Fucose (Fuc)
 - ◆ Sialic acid (Neu5Ac)

Figure 2




Figure 3




Figure 4

